Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy
暂无分享,去创建一个
H. Rammensee | L. Kanz | T. Holderried | W. Brugger | A. Heine | P. Brossart | A. Stenzl | S. Pascolo | Martin R. Müller | I. Hoerr | M. Horger | O. Maksimovic | S. M. Rittig | M. Haentschel | K. Weimer | Martin R. Müller
[1] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[2] A. Abernethy,et al. Real-world outcomes in metastatic renal cell carcinoma: insights from a Joint Community-Academic Registry. , 2014, Journal of oncology practice.
[3] A. Heine,et al. Implementing combinatorial immunotherapeutic regimens against cancer , 2014, Oncoimmunology.
[4] C. Porta,et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] L. Zitvogel,et al. Trial watch , 2013 .
[6] T. Choueiri,et al. Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria , 2013, Cancer.
[7] T. Schlake,et al. A novel, disruptive vaccination technology , 2013, Human vaccines & immunotherapeutics.
[8] N. Vogelzang,et al. Disease-Specific Survival in De Novo Metastatic Renal Cell Carcinoma in the Cytokine and Targeted Therapy Era , 2013, PloS one.
[9] U. Harmenberg,et al. Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008) , 2013, British Journal of Cancer.
[10] Laurence Zitvogel,et al. Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.
[11] T. Choueiri,et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. , 2013, The Lancet. Oncology.
[12] L. Zitvogel,et al. Trial watch , 2012, Oncoimmunology.
[13] E. Noessner,et al. Intratumoral alterations of dendritic-cell differentiation and CD8+ T-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma , 2012, Oncoimmunology.
[14] J. Blay,et al. Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. , 2012, Cancer research.
[15] Hiroaki Tanaka,et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival , 2012, Nature Medicine.
[16] P. Lara,et al. Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients. , 2012, Clinical genitourinary cancer.
[17] M. Sharpe,et al. Clinically relevant fatigue in recurrence-free prostate cancer survivors. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] T. Schlake,et al. Protein expression from exogenous mRNA: Uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway , 2011, RNA biology.
[19] H. Rammensee,et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[20] M. Grimm,et al. Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma , 2011, World Journal of Urology.
[21] Morton Ra,et al. Commentary on "Sipuleucel-T immunotherapy for castration-resistant prostate cancer". Kantoff PW, Higano CS, Shore ND, Berger , 2011 .
[22] M. Itsumi,et al. Immunotherapy for Renal Cell Carcinoma , 2010, Clinical & developmental immunology.
[23] P. Kantoff,et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.
[24] Wanling Xie,et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] G. Keating,et al. Everolimus: in advanced renal cell carcinoma. , 2009, Drugs.
[26] L. Zitvogel,et al. The Janus face of dendritic cells in cancer , 2008, Oncogene.
[27] H. Rammensee,et al. Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent , 2007, Gene Therapy.
[28] H. Rammensee,et al. Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines , 2004, Cellular and Molecular Life Sciences CMLS.
[29] E. Gilboa,et al. Cancer immunotherapy with mRNA‐transfected dendritic cells , 2004, Immunological reviews.
[30] S. Natsugoe,et al. Clinical implications of intratumoral dendritic cell infiltration in esophageal squamous cell carcinoma. , 2003, Oncology reports.
[31] Donna Niedzwiecki,et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. , 2003, Cancer research.
[32] H. Shinohara,et al. Prognostic value of tumor‐infiltrating dendritic cells expressing CD83 in human breast carcinomas , 2003, International journal of cancer.
[33] E. Gilboa,et al. Human Dendritic Cells Transfected with RNA Encoding Prostate-Specific Antigen Stimulate Prostate-Specific CTL Responses In Vitro1 , 2000, The Journal of Immunology.
[34] S. Natsugoe,et al. Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. , 2000, Cancer letters.
[35] H. Rammensee,et al. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. , 2000, European journal of immunology.
[36] C Caux,et al. Immunobiology of dendritic cells. , 2000, Annual review of immunology.
[37] M Mazumdar,et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.